Company: INDP
Filing Date: 2025-08-13
Form Type: 10-Q
Source: 0001641172-25-023333
Chunk: 20

Company: Indaptus Therapeutics, Inc.
Filing Date: 2025-08-13
Form: 10-Q
Item: Part I, Item 8
Chunk 20
---
 from the commercialization and sale of any of our
product candidates that obtain regulatory approval. We may never succeed in achieving regulatory approval for any of our product candidates.

General
and Administrative Expenses

General
and administrative expenses include compensation, employee benefits, and stock-based compensation, finance administration and human resources,
facility costs (including rent), professional service fees, and other general overhead costs to support our operations.

We
expect our general and administrative expenses to increase for the foreseeable future as we continue to increase our headcount to support
our research and development activities and operations generally, the growth of our business and, if any of our product candidates receive
marketing approval, commercialization activities. We also expect to continue to incur expenses as a result of operating as a public company,
including expenses related to compliance with the rules and regulations of the SEC, additional director and officer insurance expenses,
investor relations activities, and other administrative and professional services.

Other
Income, Net

Other
income, net includes interest earned on deposits and investments and other items of income and gain and loss that are incidental to the core operations of the Company.

3

Results
of Operations

Three
months ended June 30, 2025 compared to three months ended June 30, 2024

The
following tables set forth our results of operations for the three months ended June 30, 2025 and 2024 and the relative dollar change
between the two periods.

    Three months ended  

    June 30,  
    Change 

    2025  
    2024  
    ($)  
    % 
  
    Operating expenses: 

    Research and development 
    $2,167,114  
    $1,713,973  
    $453,141  
     26.4%
  
    General and administrative 
     2,289,649  
     2,394,912  
     (105,263) 
     (4.4)%

    Total operating expenses 
     4,456,763  
     4,108,885  
     347,878  
     8.5%

    Loss from operations 
     (4,456,763) 
     (4,108,885) 
     (347,878) 
     8.5%

    Other income, net 
     15,547  
     93,618  
     (78